Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants 18-80 years of age with active RA for at least 6 months;~* Received treatment for RA on an outpatient basis and experienced an inadequate response or intolerance to treatment with at least 1 anti-TNF alpha therapy (etanercept, infliximab or adalimumab);~* Must have received MTX for a minimum of 12 weeks, with the last 4 weeks, prior to screening at a stable dose;~* Participants with swollen joint count (SJC) and tender joint count (TJC) of at least 8 joints at screening and at randomization;~* Radiographic evidence of at least 1 joint with a definite erosion due to RA;~* Participants of reproductive potential must be using reliable contraceptive methods.~Exclusion Criteria:~* Bone or joint surgery within 8 weeks prior to screening or joint surgery planned within 24 weeks of randomization;~* Class IV functional status of RA;~* Previous treatment within 6 months with intravenous gamma globulin, or the Prosorba column;~* Intraarticular or parenteral corticosteroids within 4 weeks prior to screening visit;~* With a live vaccine within 4 weeks prior to randomization;~* Previous treatment with rituximab or other cell-depleting therapies;~* Concurrent treatment with any disease-modifying anti-rheumatic drug (except for MTX) or any anti-TNF alfa factor or other biologic therapy;~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies;~* Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders;~* Known contraindications to receiving rituximab;~* Known active bacterial, viral, fungal, mycobacterial or other infection;~* History of recurrent significant infection or history of recurrent bacterial infections;~* Primary or secondary immunodeficiency (history of, or currently active);~* History of cancer, including solid tumors and hematologic malignancies (except basal cell or squamous cell carcinoma of the skin that have been excised and cured);~* Women who are pregnant or breast-feeding;~* History of alcohol, drug or chemical abuse within 6 months prior to screening;~* Neuropathies and neurovasculopathies which might interfere with pain evaluation;~* Participants with poor peripheral venous access;~* Intolerance or contraindications to oral or intravenous corticosteroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Plus Methotrexate (Type: PLACEBO_COMPARATOR): Participants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.
- Rituximab plus Methotrexate (Type: EXPERIMENTAL): Participants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete